Skip to main content

IPI-9119 (C09-1140-037)

Aladdin

Catalog No.
C09-1140-037
Manufacturer No.
I648545-5mg
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $601.08
List Price: $667.87

IPI-9119 is an orally active, selective and irreversible FASN inhibitor with an IC 50 of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse modelsIn VitroIPI-9119

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
IPI-9119 is an orally active, selective and irreversible FASN inhibitor with an IC 50 of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse modelsIn VitroIPI-9119 inhibits FASN in cellular occupancy assays (IC 50 ∼10nM), and shows more than 400-fold selectivity against several additional serine hydrolases. IPI-9119 (0.1-0.5 μM; 6 days) inhibits cell growth and induces cell cycle arrest, apoptosis. IPI-9119 (0.05-5 μM; 6 days) inhibits AR-FL and AR-V7 protein expression. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Prostate cancer (PCa) cells (AD LNCaP, AI C4-2, LNCaP-95 and 22Rv1 AI cells) Concentration: 0.1, 0.5 μM Incubation Time: 6 days Result: Inhibited PCa cell growth. Had no growth inhibition in FASN KO PCa cells. Cell Cycle AnalysisCell Line: PCa cells Concentration: 0.1, 0.5 μM Incubation Time: 6 days Result: Reduced the proportion of S-phase cells and increased that of G0/G1-, sub-G1–phase cells and decreased expression of cyclin A2. Western Blot AnalysisCell Line: PCa cells Concentration: 0.05, 0.1, 0.25, 0.5, 5 μM Incubation Time: 6 days Result: Significantly decreased AR-FL protein levels in AD LNCaP, AI C4-2 cells (expressing only AR-FL) and reduced the expression of AR-V7 in LNCaP-95, 22Rv1 AI cells driven by this variant.In VivoIPI-9119 (SC pump infusion; 0.5 μL/h; 100 mg/mL; for 28 days) inhibits tumor growth of CRPC xenografts mouse models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 8-10-week male Ncr Nu Castrated mice or castrated NOD male SCID with 22Rv1 or LNCaP-95 cells Dosage: 100 mg/mL Administration: SC pump infusion (0.5 μL/h; 100 mg/mL); for 28 days Result: Inhibited tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models.Form:SolidIC50& Target:IC50: 0.3 nM (FASN). Specification: 0.98 Molecular Formula: C24H19F2N5O5 Molecular Weight: 495.43 PubChem CID: 68208572 Isomeric SMILES: CC(C)N(C1=C(C=C(C=C1)C(=O)O)OC2=CC=CC=C2)C(=O)N3C(=O)N(N=N3)C4=C(C=CC=C4F)F
UPC:
12352005
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
I648545-5mg
CAS:
1346564-56-4
Product Size:
5mg


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.